Moderna, Inc. (MRNA) Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum September 23, 2026 8:50 AM EDT
Company Participants
Stéphane Bancel – CEO & Director
David Berman – Chief Development Officer
Conference Call Participants
Courtney Breen – Bernstein Institutional Services LLC, Research Division
Presentation
Courtney Breen
Bernstein Institutional Services LLC, Research Division
Wonderful. Hi, everyone. Thank you so much for being with us here today. My name is Courtney Breen. I am the pharma analyst here at Bernstein. And I have the privilege of sharing the stage today with Stéphane Bancel, CEO of Moderna; as well as David Berman, recently joined Chief Development Officer at Moderna as well. It is — I’m looking forward to a fun conversation. There’s lots going on with the company at the moment. Stock price is moving a huge amount at the moment as well. So there’s lots of news ahead and kind of we’re certainly excited for ESMO.
Question-and-Answer Session
Courtney Breen
Bernstein Institutional Services LLC, Research Division
Perhaps just to start really big and broad for those who haven’t been following the company as closely, although I don’t imagine that’s many. Some may know Moderna as kind of a COVID or vaccines company. In a couple of minutes, what’s Moderna today and what is the most material things that have changed in the last 12 months?
Stéphane Bancel
CEO & Director
All right. Good morning. It’s a great question. Actually, Moderna has never been a COVID-19 vaccine company.
Courtney Breen
Bernstein Institutional Services LLC, Research Division
Exactly.
Stéphane Bancel
CEO & Director
I know most people think of a company like this. Moderna has been, since day 1, an mRNA platform company, as you know. And we’ve always built the company in terms of how do we maximize the value of the company by developing
